Aleta Biotherapeutics, Inc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aleta Biotherapeutics, Inc - overview
Established
2006
Location
Natick, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2006, Aleta Biotherapeutics, Inc provides multi-antigen targeting solutions for cell therapy. The company was co-founded by Roy Lobb, and as of 2023, the firm is headed by its CEO Paul Rennert. In November 2022, the firm received Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001 from U. K.
Medicines and Healthcare Products Regulatory Agency (MHRA). The company offers cell therapeutics for the treatment of advanced hematologic cancers and refractory solid tumors. The firm science includes Aleta CAR T engagers which can transform the expression of any cancer tumor cell. The firm has developed various platforms for cancer treatment such as ALETA-001, ALETA-004, ALETA-005, ALETA-002, and ALETA-003.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.aletabio.com/
Total Amount Raised
Subscriber access only
Aleta Biotherapeutics, Inc - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.